Indoco Remedies Ltd
NSE:INDOCO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (46.8), the stock would be worth ₹-314.12 (249% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -31.5 | ₹211.45 |
0%
|
| 3-Year Average | 46.8 | ₹-314.12 |
-249%
|
| 5-Year Average | 44.9 | ₹-301.49 |
-243%
|
| Industry Average | 57.9 | ₹-389.14 |
-284%
|
| Country Average | 49.7 | ₹-334.21 |
-258%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Indoco Remedies Ltd
NSE:INDOCO
|
19.5B INR | -31.5 | -17.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 61.1 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 21 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 50.3 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 16.4 | 19.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 12 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 22.9 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 24.4 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 19.3 | 16.6 |
Market Distribution
| Min | 0.6 |
| 30th Percentile | 27.4 |
| Median | 49.7 |
| 70th Percentile | 92 |
| Max | 57 010.1 |
Other Multiples
Indoco Remedies Ltd
Glance View
Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-01-07. The firm is an integrated, research-oriented pharma company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm's geographical segments include India and Outside India. The firm has nine domestic marketing divisions with a brand portfolio in various therapeutic segments, including Gastrointestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management and Gyneacology. The Company’s brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cal-Aid, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM and Methycal.
